Tumor-specific promoter-driven adenoviral therapy for insulinoma

Conclusions INSM1 promoter-driven conditionally replicating adenoviruses may serve as a new tool for the treatment of insulinoma and may provide clinicians with additional options to combat this disease.

http://link.springer.com/10.1007/s13402-016-0274-8

Source: Cellular Oncology - February 22, 2016 Category: Cancer & Oncology Source Type: research